Estrella Immunopharma

Estrella Immunopharma is a clinical-stage biopharmaceutical company developing T-cell therapies for blood cancers and solid tumors. Its lead candidate, EB103, is in a Phase I/II clinical trial for diffuse large B-cell lymphoma, and the company is advancing EB104 preclinically for diffuse large B-cell lymphoma and acute lymphocytic leukemia and EB201 preclinically for systemic lupus erythematosus. The company's ARTEMIS cell receptor platform is designed to develop and commercialize T-cell therapies targeting CD19 and CD22 for hematologic malignancies, and it has a collaboration with Eureka Therapeutics and Imugene covering solid-tumor treatments that combine Imugene's CF33-CD19t with EB103. Estrella Immunopharma is a subsidiary of Eureka Therapeutics and is headquartered in Emeryville, California. The company trades on the Nasdaq Capital Market, where it disclosed on September 1, 2026 that it had received a notification of non-compliance with continued listing standards, and it has until March 1, 2027 to restore its market value of listed securities above $35 million for at least ten consecutive days.